73 related articles for article (PubMed ID: 10565845)
21. A Mouse Model for Binge-Level Methamphetamine Use.
Shabani S; Houlton SK; Hellmuth L; Mojica E; Mootz JR; Zhu Z; Reed C; Phillips TJ
Front Neurosci; 2016; 10():493. PubMed ID: 27853417
[TBL] [Abstract][Full Text] [Related]
22. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
23. Methamphetamine alters microglial immune function through P2X7R signaling.
Fernandes NC; Sriram U; Gofman L; Cenna JM; Ramirez SH; Potula R
J Neuroinflammation; 2016 Apr; 13(1):91. PubMed ID: 27117066
[TBL] [Abstract][Full Text] [Related]
24. Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.
Banks ML; Smith DA; Kisor DF; Poklis JL
Pharmacol Biochem Behav; 2016 Feb; 141():58-65. PubMed ID: 26656213
[TBL] [Abstract][Full Text] [Related]
25. The long-term effects of methamphetamine exposure during pre-adolescence on depressive-like behaviour in a genetic animal model of depression.
Mouton M; Harvey BH; Cockeran M; Brink CB
Metab Brain Dis; 2016 Feb; 31(1):63-74. PubMed ID: 26581673
[TBL] [Abstract][Full Text] [Related]
26. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
28. Pavlovian discriminative stimulus effects of methamphetamine in male Japanese quail (Coturnix japonica).
Levi Bolin B; Singleton DL; Akins CK
J Exp Anal Behav; 2014 Jul; 102(1):126-38. PubMed ID: 24965811
[TBL] [Abstract][Full Text] [Related]
29. Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum.
Chauhan H; Killinger BA; Miller CV; Moszczynska A
Int J Mol Sci; 2014 Apr; 15(4):5884-906. PubMed ID: 24717411
[TBL] [Abstract][Full Text] [Related]
30. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
31. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
32. Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites.
Peterson EC; Celikel R; Gokulan K; Varughese KI
PLoS One; 2013; 8(12):e82690. PubMed ID: 24349338
[TBL] [Abstract][Full Text] [Related]
33. A stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence.
Shen H; Mohammad A; Ramroop J; Smith SS
Neuroscience; 2013 Dec; 254():452-75. PubMed ID: 23994152
[TBL] [Abstract][Full Text] [Related]
34. Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion.
Singh RA; Kosten TA; Kinsey BM; Shen X; Lopez AY; Kosten TR; Orson FM
Pharmacol Biochem Behav; 2012 Dec; 103(2):230-6. PubMed ID: 23010423
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
[TBL] [Abstract][Full Text] [Related]
36. Distinct neurochemical adaptations within the nucleus accumbens produced by a history of self-administered vs non-contingently administered intravenous methamphetamine.
Lominac KD; Sacramento AD; Szumlinski KK; Kippin TE
Neuropsychopharmacology; 2012 Feb; 37(3):707-22. PubMed ID: 22030712
[TBL] [Abstract][Full Text] [Related]
37. Extended access methamphetamine decreases immature neurons in the hippocampus which results from loss and altered development of neural progenitors without altered dynamics of the S-phase of the cell cycle.
Yuan CJ; Quiocho JM; Kim A; Wee S; Mandyam CD
Pharmacol Biochem Behav; 2011 Nov; 100(1):98-108. PubMed ID: 21855565
[TBL] [Abstract][Full Text] [Related]
38. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.
Kehr J; Ichinose F; Yoshitake S; Goiny M; Sievertsson T; Nyberg F; Yoshitake T
Br J Pharmacol; 2011 Dec; 164(8):1949-58. PubMed ID: 21615721
[TBL] [Abstract][Full Text] [Related]
39. Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat.
Keller CM; Salvatore MF; Pruett BS; Guerin GF; Goeders NE
Psychopharmacology (Berl); 2011 Jun; 215(3):513-26. PubMed ID: 21523347
[TBL] [Abstract][Full Text] [Related]
40. Extended access to methamphetamine self-administration affects sensorimotor gating in rats.
Hadamitzky M; Markou A; Kuczenski R
Behav Brain Res; 2011 Mar; 217(2):386-90. PubMed ID: 21070821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
